Clinical Trials Logo
  1. Home
  2. Type 1 Diabetes Mellitus
  3. NCT00703599
  4. Details
NCT00703599 Clinical Trial

Safety and Efficacy of Autologous Adipose-Derived Stem Cell Transplantation in Patients With Type 1 Diabetes

Type 1 Diabetes Mellitus Clinical Trial

Official title:
Phase I/II Study of Intravenous Administration of Activated Autologous Adipose-Derived Stromal Vascular Fraction in Patients With Type 1 Diabetes

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT00703599
Other study ID # Ad-003
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received June 19, 2008
Last updated June 28, 2008
Start date November 2007
Est. completion date December 2009

Study information
Verified date June 2008
Source Adistem Ltd
Contact Letitia Lucero-Palma, MD
Phone 63-916-478-7512
Email lettielucero@yahoo.com
Is FDA regulated No
Health authority Philippines: Department of Health
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether intravenous administration of autologous adipose stem cells is safe and beneficial in patients with type 1 diabetes.

Description:

Diabetes Mellitus is of large epidemic proportions worldwide. It is proliferating at such a fast rate that new novel drugs and other therapeutic approaches are required. The purpose of this Phase I/II study is to determine whether the intravenous administration of activated adipose-derived stromal vascular fraction as a single procedure is safe and efficacious in patients with Type 1 Diabetes Mellitus. Patients will be observed over 12 months following the procedure, with 2 weeks, 1 month and tri-monthly diagnostics and life style questionaires.

Recruitment information / eligibility
Status Recruiting
Enrollment 30
Est. completion date December 2009
Est. primary completion date November 2009
Accepts healthy volunteers No
Gender Both
Age group 16 Years to 60 Years
Eligibility Inclusion Criteria:

- Confirmed diagnosis of Type I diabetes for at least 2 years

- Insulin-dependent

Exclusion Criteria:

- Presence of acute diabetic complications in the acute stage as recent myocardial infarction, recent CVA or acute renal failure.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Procedure:
• Autologous Adipose-derived Stem cells
Intravenous administration of autologous activated stromal vascular fraction derived from 100-120 ml lipoaspirate following mini-liposuction of abdominal adipose tissue.

Locations
Country Name City State
Philippines Beverly Hills Medical Group Makati City Manila
Philippines Veterens Memorial Medical Centre Quezon City Manila

Sponsors (1)
Lead Sponsor Collaborator
Adistem Ltd

Country where clinical trial is conducted

Philippines, 

References & Publications (1)

Gimble JM, Katz AJ, Bunnell BA. Adipose-derived stem cells for regenerative medicine. Circ Res. 2007 May 11;100(9):1249-60. Review. — View Citation

Outcome
Type Measure Description Time frame Safety issue
Primary Lowering of insulin-dependence and anti-hyperglycemic medication dosages At 2, 4, 12, 24, 36, and 48 weeks Yes
Secondary Lowering of glycosylated hemoglobin (HbA1C). At 4, 12, 24, 36, and 48 weeks Yes
Secondary Increased circulating C-Peptide levels At 4, 12, 24, 36, and 48 weeks. No
Secondary Increased general well-being of patients. At 2, 4, 12, 24, 36, and 48 weeks. Yes
Secondary No detrimental change seen in kidney function tests, liver function tests and other haematological parameters. At 2, 4, 12, 24, 36, and 48 weeks. Yes
See also
  Status Clinical Trial Phase
Completed NCT04476472 - Omnipod Horizon™ Automated Glucose Control System Preschool Cohort N/A
Completed NCT03635437 - Evaluation of Safety and Diabetes Status Upon Oral Treatment With GABA in Patients With Longstanding Type-1 Diabetes Phase 1/Phase 2
Completed NCT04909580 - Decision Coaching for Youth and Parents Considering Insulin Delivery Methods for Type 1 Diabetes N/A
Active, not recruiting NCT00679042 - Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol Phase 3
Completed NCT03293082 - Preschool CGM Use and Glucose Variability in Type 1 Diabetes N/A
Completed NCT04016662 - Automated Insulin Delivery in Elderly With Type 1 Diabetes (AIDE T1D) Phase 4
Completed NCT02527265 - Afrezza Safety and Pharmacokinetics Study in Pediatric Patients Phase 2
Completed NCT03738865 - G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes Phase 3
Completed NCT03240432 - Wireless Innovation for Seniors With Diabetes Mellitus N/A
Completed NCT03168867 - Effectiveness Trial of an E-Health Intervention To Support Diabetes Care in Minority Youth (3Ms) N/A
Completed NCT03674281 - The VRIF Trial: Hypoglycemia Reduction With Automated-Insulin Delivery System N/A
Completed NCT03669770 - Ultrasound Classification and Grading of Lipohypertrophy and Its Impact on Glucose Variability in Type 1 Diabetes
Recruiting NCT03682640 - Azithromycin Insulin Diet Intervention Trial in Type 1 Diabetes Phase 2
Recruiting NCT04096794 - Chinese Alliance for Type 1 Diabetes Multi-center Collaborative Research
Completed NCT02882737 - The Impact of Subcutaneous Glucagon Before, During and After Exercise a Study in Patients With Type 1 Diabetes Mellitus N/A
Recruiting NCT02745808 - Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes Phase 1
Completed NCT02558491 - Feasibility of a Decision Support System to Reduce Glucose Variability in Subject With T1DM N/A
Completed NCT02596204 - Diabetes Care Transformation: Diabetes Data Registry and Intensive Remote Monitoring N/A
Withdrawn NCT02518022 - How to be Safe With Alcoholic Drinks in Diabetes N/A
Withdrawn NCT02579148 - Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes Phase 1

External Links